Neogen Corporation SEC filings document material events for an operating company focused on food safety and animal safety products. Recent 8-K filings cover quarterly results and financial condition, Regulation FD disclosures related to Petrifilm manufacturing validation, and exhibits containing earnings releases and business updates.
The company’s filings also record governance and leadership matters, including executive appointments and departures, compensatory arrangements, board committee assignments, annual meeting voting results, executive compensation votes, and auditor ratification. These disclosures provide formal records of Neogen’s public-company reporting, operating updates, governance structure and shareholder matters.
Neogen Corporation Schedule 13G/A (Amendment No. 2): A group led by Clarkston Capital Partners, LLC reports beneficial ownership of 2,204,788 shares of Neogen common stock, equal to 1.01% of the class based on 217,673,041 shares outstanding as of February 28, 2026. The filing attributes 1,000,000 shares to sole voting power and 1,204,788 shares to shared dispositive power across the reporting persons. The statement is filed jointly by CCP, Clarkston Companies, Inc., and reporting individuals Jeffrey A. Hakala and Gerald W. Hakala.
NEOGEN CORP Chief Accounting Officer John Patrick Moylan reported routine equity compensation activity involving company stock. On May 4, 2026, he exercised 4,558 Restricted Stock Units into common shares at $9.53 per share. To cover related tax obligations, 1,568 common shares were disposed of as a tax-withholding transaction, not an open-market sale. Following these transactions, Moylan directly holds 18,905 shares of NEOGEN common stock.
NEOGEN CORP Chief Legal Officer Stacey Jennifer Evans reported equity awards of common stock and stock options. She received 39,349 shares of Common Stock on May 1, 2026, valued at $9.53 per share, and now holds that amount directly.
On the same date she was granted 89,520 options to buy Common Stock at an exercise price of $9.53 per share, expiring on May 1, 2036. According to the footnote, these options and related RSUs vest in equal annual installments over three years, making this a multi-year compensation grant rather than an open-market trade.
Neogen Corp reports a Schedule 13G filing showing Vanguard Capital Management beneficially owns 11,164,628 shares of Common Stock, representing 5.13% of the class as of 03/31/2026.
The filing states Vanguard Capital Management has sole voting power over 1,599,582 shares and sole dispositive power over 11,164,628 shares. The report is signed by Ashley Grim on 04/30/2026 and notes holdings include shares held for Vanguard funds and managed accounts.
Neogen Corp reported beneficial ownership disclosed by Vanguard Portfolio Management. Vanguard Portfolio Management LLC reported beneficial ownership of 12,916,330 shares, representing 5.93% of Common Stock as of 03/31/2026. The filing states Vanguard exercises dispositive power through affiliated investment vehicles and lists sole voting power of 84,066 shares. The filing is signed by Ashley Grim on 04/29/2026.
Neogen Corporation filed a current report describing upcoming investor outreach and progress on product validation. The company plans to host two investor tours of its Petrifilm manufacturing facility in Lansing, Michigan on April 20, 2026 and April 21, 2026.
Neogen states it has successfully completed multiple operational qualifications for certain Petrifilm single kit units and is now proceeding with multiple performance qualifications for these SKUs as part of its broader validation efforts. This technical and validation update will be shared with investors during the facility tours.
NEOGEN CORP filed an insider ownership report for Chief Legal Officer Stacey Jennifer Evans. The filing lists her as an officer reporting person but shows no reported share transactions or derivative positions, and no current holdings entries, in the summarized data provided.
Neogen Corporation reported fiscal third quarter 2026 revenue of $211.2 million, down 4.4% from $221.0 million a year earlier, and posted a net loss of $17.0 million, or $(0.08) per diluted share. Food Safety sales grew 2.6% to $156.7 million, while Animal Safety revenue fell 20.1% to $54.5 million due to third‑party supplier issues.
On an adjusted basis, Neogen generated Adjusted EBITDA of $48.2 million with a 22.8% margin and Adjusted Net Income of $19.4 million, or $0.09 per share. The company raised its fiscal 2026 revenue outlook to $857–$860 million and maintained Adjusted EBITDA guidance of about $175 million.
Neogen also agreed to sell its global Genomics business to Zoetis for $160.0 million, expecting roughly $140.0 million of net cash proceeds to support a targeted net debt‑to‑Adjusted EBITDA ratio of less than three times by the end of calendar 2026. The Petrifilm manufacturing transition remains on track for completion by November 2026.
Neogen Corporation reported a leadership change in its legal function. The company announced that its Chief Legal and Administrative Officer, Amy Rocklin, will leave the company. Her departure is effective March 31, 2026, following the company’s announcement on March 30, 2026.